# US 2021/0230250 A1 · Novel ctla4-ig immunoadhesins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0230250 A1
- Document ID: US20210230250A1
- Status: Published application
- Kind: A1
- Application number: 17/231,848
- Filed: 2021-04-15
- Published: 2021-07-29
- Earliest claimed: 2010-02-19
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Gregory A. Lazar; Matthew J. Bernett
- Web page: https://patentgrep.com/patent/US20210230250A1

## CPC

- C07K 14/70521: {CD28, CD152}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.

## Claims

### Claim at position 1

-8. (canceled)

### Claim 9

An immunoadhesin comprising a first domain comprising a variant CTLA4 and a second domain comprising an IgG Fc region, wherein the variant CTLA4 comprises SEQ ID NO: 31.

### Claim 10 (depends on 9)

The immunoadhesin of claim 9, wherein the IgG Fc region comprises a combination of substitutions of M428L/N434S, wherein amino acid numbering is according to the EU index.

### Claim 11 (depends on 10)

The immunoadhesin of claim 10, wherein the IgG Fc region is an IgG2 Fc region

### Claim 12 (depends on 10)

The immunoadhesin of claim 10, wherein the immunoadhesin comprises SEQ ID NO: 37.

### Claim 13 (depends on 12)

A pharmaceutical composition comprising the immunoadhesin of claim 12 and a pharmaceutically acceptable excipient.

### Claim 14 (depends on 12)

A method of treating an autoimmune disease selected from one or more of Crohn's disease, systemic Erythmatus Lupus, lupus nephritis, psoriatic arthritis, psoriasis, rheumatoid arthritis, ulcerative colitis or transplant rejection, comprising administering the immunoadhesin of claim 12.
